Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › neuropathy

Neuropathy

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for neuropathy

16 trials tracked for neuropathy: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 238 citations.

16Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 5 Phase 1 1 Other / NA 7
  1. Phase 3 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Completed · 238 cited
  2. Phase 3 S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo Completed · 214 cited
  3. Phase 3 Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Completed
  4. Phase 2 A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN) Completed
  5. Phase 2 The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy Completed
  6. Phase 2 Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies Completed
Show 10 more trials
  1. Phase 2 Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy Completed
  2. Phase 2 Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL) Completed
  3. Phase 1 Study to Investigate the Effect of AB-101 in Breast Cancer Survivors Completed
  4. N/A Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy Completed
  5. N/A Pregabalin in CIPN Completed
  6. N/A Electro-acupuncture for the Prevention of Taxane Induced Myalgias and Neuropathy Completed
  7. N/A A Wearable "Balance Booster" - Stepping Closer to the Market Completed
  8. N/A Tango for Neuropathy Among Breast Cancer Survivors Completed
  9. N/A Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy Completed
  10. N/A Effect of the Erchonia® EVRL OTC™ for the Relief of Diabetic Peripheral Neuropathy Foot Pain Completed

Showing the 16 most-cited and recently-updated of 16 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Neuropathy: what the trials found

Clinical data regarding chemotherapy-induced neuropathy and related interventions show varied outcomes. In studies evaluating calcium gluconate, research identified specific cumulative oxaliplatin doses (approximately 8.0 to 8.4) that could be administered without dose-limiting chronic neurotoxicity (p=0.89) 1.

Assessments of acetyl-L-carnitine hydrochloride for neuropathy did not show statistically significant differences compared to placebo in terms of FACT-Taxane Neurotoxicity Model-adjusted scores (p=0.17), FACT-Trial Outcome Index (TOI) functional status (p=0.92), or FACIT-fatigue scores (p=0.20) 2.

In trials evaluating Carboplatin, the assessment of Paclitaxel/Carboplatin induced peripheral neuropathy via EORTC QLQ-CIPN20 showed no significant difference between groups (p=0.21). Additionally, very low percentages of patients required chemotherapy delays or dose reductions due to peripheral neuropathy 3.

Recent results — preliminary, needs further review

  • Rhythmic Auditory Stimulation was evaluated for neuropathy symptoms and cancer-related fatigue; however, results showed mixed outcomes in symptom scores (6.68 vs 3.29) and BFI scores (8.56 vs 1.21) 10.

For the clinician treating this condition

  • Oxaliplatin administration can be managed with specific cumulative dose thresholds to avoid dose-limiting chronic neurotoxicity 1.
  • Acetyl-L-carnitine hydrochloride did not demonstrate statistically significant improvements in functional status or fatigue scores compared to placebo in the studied cohort 2.
  • Carboplatin/Paclitaxel regimens showed low rates of treatment delays or dose reductions specifically due to peripheral neuropathy 3.

AI synthesis of 4 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
High prevalence of microvascular and macrovascular complications among adult Ugandans with diabetes
Diabetes & Endocrinology Meta-analysis
High prevalence of microvascular and macrovascular complications among adult Ugandans with diabetes High rates of diabetes complications found in adult Ugandans
This meta-analysis examined the prevalence of various diabetic complications, including neuropathy and retinopathy, in a large cohort of adu…
More than half of Ugandan adults with diabetes suffer from nerve damage, highlighting a critical need for earlier screening and better care.
Jun 12, 2026
Narrative review discusses Ganoderma lucidum polysaccharides for diabetes and related complications
Diabetes & Endocrinology Sys. Review
Narrative review discusses Ganoderma lucidum polysaccharides for diabetes and related complications New research shows mushroom compounds may help control blood sugar and fix organ damage
This narrative review examines the theoretical potential of Ganoderma lucidum polysaccharides (GLPs) for diabetes and associated conditions.
A common mushroom extract could help lower blood sugar and heal organ damage for millions of people with diabetes
Frontiers May 1, 2026